Andere Sprachen Nuwellis, Inc.

Aktien

A3DZZT

US67113Y4052

NUWE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
0,18 ^USD	-12,62 %		+7,27 %	-69,01 %

02.05.	Nuwellis, Inc. erhält USPTO-Bescheid über die Erteilung eines Patents für innovative pädiatrische CRRT-Technologie	CI
29.04.	NUWELLIS, INC. : Maxim gibt eine neutrale Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02.05.
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02.05.
Nuwellis Announces Closing of $2.7 Million Public Offering	01.05.
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024	30.04.
Nuwellis Announces Pricing of $2.7 Million Public Offering	26.04.
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09.04.
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09.04.
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	07.03.
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	07.03.
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	06.03.
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	05.03.
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	05.03.
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	27.02.
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	22.02.
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20.02.
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference	20.02.
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload	06.02.
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16.01.
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16.01.
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	16.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nuwellis, Inc.

Aktien

A3DZZT

US67113Y4052

NUWE

Andere Sprachen

Filter